GT199200028A - Derivados de quinuclidina - Google Patents

Derivados de quinuclidina

Info

Publication number
GT199200028A
GT199200028A GT199200028A GT199200028A GT199200028A GT 199200028 A GT199200028 A GT 199200028A GT 199200028 A GT199200028 A GT 199200028A GT 199200028 A GT199200028 A GT 199200028A GT 199200028 A GT199200028 A GT 199200028A
Authority
GT
Guatemala
Prior art keywords
compounds
quinuclidine derivatives
disorders
antagonists
mind
Prior art date
Application number
GT199200028A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24845673&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT199200028(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT199200028A publication Critical patent/GT199200028A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A NUEVOS DERIVADOS DE QUINUCLIDINA, A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN ESTOS COMPUESTOS Y AL USO DEESTOS COMPUESTOS EN EL TRATAMIENTO DE LOS TRASTORNOS GASTROINTESTINALES, TRASTORNOS INFLAMATORIOS, TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL Y DOLOR. ESTOS COMPUESTOS SON ANTAGONISTAS DE LA SUSTANCIA P Y TIENEN LA ESTRUCTURA QUIMICA CONTENIDA EN LA FICHA TECNICA RESPECTIVA Y LAS SALES FARMACEUTICA MENTE ACEPTABLES DE DICHOS COMPUESTOS.
GT199200028A 1991-05-31 1992-05-29 Derivados de quinuclidina GT199200028A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70840491A 1991-05-31 1991-05-31

Publications (1)

Publication Number Publication Date
GT199200028A true GT199200028A (es) 1993-11-20

Family

ID=24845673

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199200028A GT199200028A (es) 1991-05-31 1992-05-29 Derivados de quinuclidina

Country Status (41)

Country Link
US (3) US5807867A (es)
EP (1) EP0587723B1 (es)
JP (2) JPH0733386B2 (es)
KR (1) KR100214905B1 (es)
CN (1) CN1048492C (es)
AP (1) AP299A (es)
AT (1) ATE135006T1 (es)
AU (1) AU657552B2 (es)
BG (1) BG61694B1 (es)
BR (1) BR9206073A (es)
CA (1) CA2102179C (es)
CZ (1) CZ281403B6 (es)
DE (4) DE122006000066I1 (es)
DK (1) DK0587723T3 (es)
EG (1) EG19944A (es)
ES (1) ES2084361T3 (es)
FI (1) FI114475B (es)
GR (1) GR3019687T3 (es)
GT (1) GT199200028A (es)
HU (1) HU217548B (es)
IE (1) IE72473B1 (es)
IL (1) IL102008A (es)
IS (1) IS1611B (es)
LU (1) LU91293I2 (es)
MA (1) MA22539A1 (es)
MX (1) MX9202554A (es)
NL (1) NL300250I2 (es)
NO (2) NO302701B1 (es)
NZ (2) NZ270673A (es)
OA (1) OA09867A (es)
PL (1) PL171379B1 (es)
PT (1) PT100546B (es)
RO (1) RO110499B1 (es)
RU (1) RU2103269C1 (es)
SK (1) SK390692A3 (es)
TW (1) TW204349B (es)
UA (1) UA27776C2 (es)
UY (1) UY23422A1 (es)
WO (1) WO1992021677A1 (es)
YU (1) YU48995B (es)
ZA (1) ZA923942B (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0587723T3 (da) * 1991-05-31 1996-04-01 Pfizer Quinuclidinderivater
ATE142199T1 (de) * 1991-06-20 1996-09-15 Pfizer Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen
PT655996E (pt) * 1992-08-19 2002-04-29 Pfizer Benzilaminas substituidas contendo heterociclicos nao aromaticos contendo azoto
KR950704311A (ko) * 1992-11-12 1995-11-17 알렌 제이. 스피겔 물질 p 길항체로서의 퀴누클리딘 유도체(quinuclidine derivative as substance p antagonist)
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (en) * 1993-11-17 1995-10-11 Pfizer Substance P antagonists for the treatment or prevention of sunburn.
EP0659409A3 (en) * 1993-11-23 1995-08-09 Pfizer Substance P antagonists for the inhibition of angiogenesis.
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
KR20010041991A (ko) * 1998-03-19 2001-05-25 다케다 야쿠힌 고교 가부시키가이샤 복소환식 화합물, 그의 제조법 및 타키키닌 수용체길항약으로서의 용도
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
ES2304984T3 (es) 1999-11-03 2008-11-01 Amr Technology, Inc. Tetra-hidroisoquinolinas de sustitucion arilica y heteroarilica y su utilizacion para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
BR0112350A (pt) 2000-07-11 2003-06-24 Albany Molecular Res Inc Composto, composição farmacêutica, e, método de tratar um animal afligido por um distúrbio neurológico ou psicológico
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
CZ200434A3 (cs) * 2001-07-20 2005-02-16 Pfizer Products Inc. Léčivo pro léčení abnormálního úzkosného chování u domácích zvířat a způsob screeningu zkoušené sloučeniny za účelem stanovení anxiolytické účinnosti u psů
US6686507B2 (en) 2002-03-06 2004-02-03 Pfizer Inc Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
WO2005045395A2 (en) * 2003-10-27 2005-05-19 Meyer Donald W Method of detecting bovine spongiform encephalopathy
CA2547283C (en) * 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
SI1713504T1 (sl) * 2004-01-30 2017-10-30 Zoetis Services Llc Protimikrobni konzervansi za dosego večodmerne formulacije z uporabo beta-ciklodekstrinov za tekoče odmerne oblike
EP1713479A1 (en) 2004-01-30 2006-10-25 Pfizer Products Incorporated Nk-1 receptor antagonists anesthesia recovery
PL1713801T3 (pl) * 2004-02-02 2008-04-30 Pfizer Products Incorporated Sposób wytwarzania 1-(2S,3S)-2-benzhydrylo-N-(5-tert-butylo-2-metoksybenzylo)chinuklidyno-3-aminy
KR101389246B1 (ko) 2004-07-15 2014-04-24 브리스톨-마이어스스퀴브컴파니 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
RS51780B (en) 2007-01-10 2011-12-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. INDASOLS SUBSTITUTED BY AMIDE AS INHIBITORS OF POLY (ADP-Ribose) POLYMERASES (PARP)
CA2676357A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
JP2012526823A (ja) 2009-05-12 2012-11-01 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール、ヘテロアリール、および複素環置換テトラヒドロイソキノリンならびにそれらの使用
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
DK2729147T3 (en) 2011-07-04 2017-12-18 Irbm - Science Park S P A NK-1 RECEPTOR ANTAGONISTS FOR TREATMENT OF CORNOVA
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
RU2660349C2 (ru) 2012-11-28 2018-07-05 Мерк Шарп И Доум Корп. Композиции и способы для лечения злокачественной опухоли
MX2015008196A (es) 2012-12-20 2015-09-16 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
CA3059418A1 (en) 2017-04-10 2018-10-18 Chase Therapeutics Corporation Nk1-antagonist combination and method for treating synucleinopathies
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
CA3104811C (en) 2017-06-30 2024-05-28 Chase Therapeutics Corporation Composition comprising pramipexole and nk1-antagonists for treating depression
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019162519A1 (en) 2018-02-26 2019-08-29 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
KR102102109B1 (ko) * 2018-07-10 2020-04-20 성균관대학교산학협력단 N-벤즈히드릴 퀴뉴클리딘 유도체를 포함하는 나트륨 누출 채널 억제용 조성물
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
EP0532527B1 (en) * 1990-06-01 1994-11-09 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
DE4026743A1 (de) * 1990-08-24 1992-02-27 Teves Gmbh Alfred Blockiergeschuetzte bremsanlage fuer kraftfahrzeuge
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
DK0587723T3 (da) * 1991-05-31 1996-04-01 Pfizer Quinuclidinderivater
ES2149767T5 (es) * 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
ATE194342T1 (de) * 1996-01-19 2000-07-15 Lonza Ag Verfahren zur herstellung von optisch aktivem 3- chinuclidinol
US5990125A (en) * 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer

Also Published As

Publication number Publication date
JPH07285965A (ja) 1995-10-31
US6222038B1 (en) 2001-04-24
YU48995B (sh) 2003-04-30
FI114475B (fi) 2004-10-29
UY23422A1 (es) 1992-11-12
KR100214905B1 (ko) 1999-08-02
CN1048492C (zh) 2000-01-19
FI935297A (fi) 1993-11-29
PT100546B (pt) 1999-12-31
IS1611B (is) 1996-10-18
NL300250I2 (nl) 2007-03-01
NO934312L (no) 1993-11-29
NO302701B1 (no) 1998-04-14
JPH0733386B2 (ja) 1995-04-12
SK278788B6 (sk) 1998-02-04
TW204349B (es) 1993-04-21
PT100546A (pt) 1993-08-31
HU217548B (hu) 2000-02-28
US5939433A (en) 1999-08-17
ES2084361T3 (es) 1996-05-01
CA2102179A1 (en) 1992-12-01
DE122006000066I2 (de) 2007-12-06
IL102008A0 (en) 1992-12-30
MX9202554A (es) 1992-11-01
BG98248A (bg) 1994-07-29
DE69208877T2 (de) 1996-07-25
DE69208877D1 (de) 1996-04-11
IL102008A (en) 1995-12-08
LU91293I2 (fr) 2007-02-06
OA09867A (en) 1994-08-15
ZA923942B (en) 1993-11-29
IS3871A (is) 1992-12-02
AP299A (en) 1994-01-14
US5807867A (en) 1998-09-15
NO2007003I1 (no) 2007-03-26
UA27776C2 (uk) 2000-10-16
GR3019687T3 (en) 1996-07-31
EG19944A (en) 1997-02-27
HUT70151A (en) 1995-09-28
EP0587723B1 (en) 1996-03-06
DE9290063U1 (de) 1994-02-24
CZ390692A3 (en) 1994-02-16
NO2007003I2 (no) 2011-04-18
RO110499B1 (ro) 1996-01-30
DE122006000066I1 (de) 2007-03-22
YU56492A (sh) 1995-03-27
CZ281403B6 (cs) 1996-09-11
AU1990192A (en) 1993-01-08
NZ270673A (en) 1997-07-27
NL300250I1 (nl) 2007-02-01
SK390692A3 (en) 1998-02-04
NO934312D0 (no) 1993-11-29
FI935297A0 (fi) 1993-11-29
IE72473B1 (en) 1997-04-23
IE921729A1 (en) 1992-12-02
BG61694B1 (bg) 1998-03-31
BR9206073A (pt) 1994-12-06
NZ242956A (en) 1995-06-27
RU2103269C1 (ru) 1998-01-27
CN1067428A (zh) 1992-12-30
MA22539A1 (fr) 1992-12-31
HU9303393D0 (en) 1994-03-28
AU657552B2 (en) 1995-03-16
ATE135006T1 (de) 1996-03-15
EP0587723A1 (en) 1994-03-23
WO1992021677A1 (en) 1992-12-10
JP2645225B2 (ja) 1997-08-25
AP9200384A0 (en) 1992-07-31
CA2102179C (en) 1998-10-27
JPH06504292A (ja) 1994-05-19
DK0587723T3 (da) 1996-04-01
PL171379B1 (en) 1997-04-30

Similar Documents

Publication Publication Date Title
GT199200028A (es) Derivados de quinuclidina
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
MX9301348A (es) Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende.
AR034283A1 (es) Compuestos heterociclilindazol y azaindazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento
ECSP941156A (es) 3 bencilaminometil piperidinas substituidas con heteroarilamino y heteroarilsulfonamido y compuestos afines
MX9305947A (es) Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
GT199700095A (es) Derivados 6,5-heterobiciclicos sustituidos.
GT199700089A (es) Derivados 6.6 o 6.7 -biciclicos sustituidos que contienen pirido o pirimido.
SE8700499D0 (sv) Novel pharmacologically active compounds
AR029454A1 (es) Derivados de piperazina sustituidos, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la elaboracion de medicamentos
SV1998000029A (es) Compuestos de pirazina ref. pg3186
PA8442201A1 (es) Derivados de 6-fenilpiridil-2-amina
ES2171884T3 (es) Compuestos de quinazolina.
GT199700033A (es) Derivados de 6-fenilpiridil-2-amina.
AR007118A1 (es) 4(3h)-quinazolinonas 2,3 disustituidas y composiciones farmaceuticas que las contienen
MX9307062A (es) Derivado de quinuclidina para el tratamiento de los trastornos inflamatorios y del sistema nervioso central.
ES2057490T5 (es) Derivados heterociclicos de acilaminotiazoles, su preparacion y composiciones farmaceuticas que los contienen.
ES2084579T3 (es) Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol.
MX9300616A (es) Compuestos antagonistas del receptor 5-hidroxitriptamina, proceso para su prepararcion y composicion farmaceutica que los contiene
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
LV10954A (lv) Benzimidazola atvasinajumi to iegusanas panemiens un tos saturosa farmaceitiska kompozicija
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
MX9204094A (es) Derivados de fenilalquilo, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
GT198170557A (es) 9-amino-1-hidroxioctahidrobenzo (c) quinolinas y sus deriva-dos.
MX9301157A (es) Derivados de bencimidazolona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.